Ocuphire Pharma Investor Day Presentation Deck

RM 70 Go-To-Market Strategy for 2023 Nyxol as RM Allows Efficient Pharmaceutical Launch Across Eye Care Practices Ocuphire Preferred Go-To Market Strategy for 2023 Partner with existing commercial sales and distribution players that have established ophthalmic products and relationships An Efficient Launch... * No approved drug/competition * * Routine part of practice Patients daily function impacted by eye dilations Ocuphire PHARMA

View entire presentation